Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avidity Biosciences
Biotech
Why Novartis CEO was willing to pay top dollar for Avidity
Novartis may have signed off on the second-largest pharma acquisition of 2025, but, as the company’s CEO sees it—it’s never about the price tag.
James Waldron
Nov 20, 2025 4:37am
Novartis pays $12B for late-stage dystrophy biotech Avidity
Oct 26, 2025 4:01pm
Avidity's latest DMD data drop assuages safety concerns: analyst
Mar 17, 2025 2:00pm
Analysts dig into Avidity's DMD win, revealing nuances in data
Aug 12, 2024 9:24am
Avidity therapy shows possible benefit in muscular dystrophy
Jun 12, 2024 7:00am
BMS, Avidity add another $100M to cardiovascular partnership
Nov 28, 2023 6:30am
